X0202 3 2007-02-05 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001325713 Kovner Bruce C/O CAXTON ASSOCIATES 500 PARK AVENUE NEW YORK NY 10022 1 0 1 0 Common Stock 87954 D Common Stock 6071070 I By CxSynta LLC Series A Convertible Preferred Stock Common Stock 30131 D Series A Convertible Preferred Stock Common Stock 2154105 I By CxSynta LLC Director Stock Option (Right to Buy) 10.843 2012-07-15 Common Stock 54687 D Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which the number of shares of Common Stock was divided by 4. These shares are owned directly by CxSynta LLC and indirectly by the Reporting Person as Chairman of Caxton Corporation, the managing member of CxSynta LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Upon the closing of the Issuer's initial public offering of Common Stock, each share of Series A Convertible Preferred Stock, plus accrued dividends, will convert into a certain number of shares of Common Stock in accordance with the terms of the Issuer's Restated Certificate of Incorporation, as amended. N/A. The option vested as to 25% of the shares on July 15, 2003 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter and is currently fully vested. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of Common Stock underlying the option was divided by 4 and (ii) the exercise price of the option was multiplied by 4. /s/ Scott B. Bernstein, Attorney-in-Fact 2007-02-05